Table 2.
Baseline data at Impella 5.0/5.5 implantation time.
| Total population (n = 59) | Recovery (n = 21) | No recovery (n = 38) | p-value | |
|---|---|---|---|---|
| Cardiac arrest, n (%) | 16 (27) | 6 (29) | 10 (26) | 0.9 |
| Acute coronary syndrome, n (%) | 42 (71) | 16 (76) | 26 (68) | 0.5 |
| - STEMI, n (%) | 39 (93) | 16 (100) | 23 (89) | 0.2 |
| - High risk NSTEMI, n (%) | 3 (7) | 0 (0) | 3 (11) | 0.5 |
| Worst inotropic score | 20 (11–30) | 20 (13–30) | 20 (13–30) | 0.7 |
| Mechanical ventilation, n (%) | 57 (97) | 20 (95) | 37 (97) | 0.7 |
| Any MCS pre-Impella, n (%) | 53 (90) | 18 (86) | 35 (92) | 0.4 |
| MCS pre-Impella, days | 2 (1–5) | 2 (1–2) | 3 (1–7) | 0.02 |
| VA-ECMO, n (%) | 19 (32) | 7 (33) | 12 (32) | 0.9 |
| VA-ECMO pre-Impella, days | 2 (1–5) | 2 (1–2) | 5 (2–11) | 0.02 |
| Other Impella device, n (%) | 37 (63) | 11 (52) | 26 (68) | 0.2 |
| Other Impella device, days | 4 (2–7) | 2 (2–2) | 5 (2–8) | 0.051 |
| INTERMACS Class 1, n(%) | 53 (90) | 17 (81) | 36 (95) | 0.09 |
| INTERMACS Class 2, n(%) | 6 (10) | 4 (19) | 2 (5) | 0.2 |
| SCAI stage D, n (%) | 22 (37) | 11 (52) | 11 (29) | 0.07 |
| SCAI stage E, n (%) | 37 (63) | 10 (48) | 27 (71) | 0.07 |
| Left ventricle ejection fraction,% | 10 (0–20) | 10 (0–23) | 10 (0–19) | 0.5 |
| Right ventricle dysfunction, n (%) | 24 (41) | 8 (38) | 16 (42) | 0.7 |
| Preserved right ventricular function, n (%) | 35 (59) | 13 (62) | 14 (58) | 0.7 |
| Creatinine, mg/dl | 2 (1.2–3.1) | 1.7 (1.1–2.9) | 2.3 (1.3–3.1) | 0.2 |
| Renal replacement therapy, N (%) | 10 (17) | 1 (5) | 9 (40) | 0.2 |
| Total bilirubin, mg/dl | 1 (0.9–2.4) | 1.1 (0.9–1.6) | 1.5 (1–2.6) | 0.2 |
| Platelets, number × mcL | 146 (72–205) | 160 (105–209) | 133 (62–200) | 0.4 |
Data are reported as median (interquartile).
MCS, mechanical circulatory support; VA-ECMO, venoarterial ECMO; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; SCAI, Society of Cardiovascular Angiography and Interventions.